FUNDRAISING & CORPORATE DEVELOPMENT
Capital should fund the next value inflection, not simply the next financing round.
We turn development logic into a financeable proposition and connect it to the right capital pathway.
THE INVESTABILITY QUESTION
Will this plan create a clear value inflection that justifies new capital?
Clear inflectionA defined milestone that creates measurable value and de-risks the next step.
Capital efficiencyRight-sized plan and use of proceeds to reach the next value inflection.
Investor fitPositioned for investors aligned with the asset, stage and geography.
OUR CAPITAL INTRODUCTION PATHWAY
1. DiagnoseAssess science, data, plan and financing gaps.
2. RedesignRefine strategy, plan and milestones.
3. PositionCraft the investor story and value narrative.
4. Access CapitalOpen the right investor pathways and dialogues.
5. GovernEstablish decision rights, milestones and visibility.
6. ExecuteDeliver milestones and communicate value.
INTEGRATED MODEL
BioBrokers × MB & Partners
Independent diligence. Strategic advisory. Aligned execution.
BioBrokers
BioBrokers is a specialist capital-markets and strategic-transactions partner supporting fundraising, investor outreach, M&A, licensing and strategic partnerships across international markets.
The collaboration combines BioBrokers' investor and transaction network with MB & Partners' independent clinical-development diligence, programme redesign and post-investment governance.
Valeriia Simanovskaia
Founder & CEO, BioBrokers
Capital Markets & Strategic Transactions
Valeriia advises companies on fundraising, M&A, licensing and strategic transactions across international markets. Her scientific background spans neuroscience, psychiatry, pharmacology and immuno-oncology.
Capital introduction is undertaken through the specialist transaction partner. MB & Partners does not present itself as a securities broker or placement agent.
WE HELP BEFORE CAPITAL INTRODUCTION
What we often change first
NEXT DECISION
